Clinical Trials

CNS

Ependymoma, Medulloblastoma, Central Nervous System Neoplasms

NCT05766514 2025-04-22

Trial of Cladribine and Low-Dose Cytarabine (LoDAC) Alternating With Decitabine vs. Hypomethylating Agents (HMA) Plus Venetoclax as Frontline Therapy for AML or High-Grade MDS in Patients Unfit for Intensive Induction

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05823480 2024-09-19

Magrolimab in Combination with Azacitidine After Allogeneic HCTin Treating Patients with High-Risk AML or MDS

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT05367401 2024-04-11

A Study of Sabatolimab and Magrolimab-based Treatment in AML or Higher Risk MDS Participants

Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT05720988 2024-03-08

Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

NCT06180863 2023-12-26

Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients

Pathologic Complete Response, Leukemia, Myeloid, Acute

NCT03932318 2023-07-20

Venetoclax, Azacitidine, and Lintuzumab-Ac225 in AML Patients

Leukemia, Myeloid, Acute

NCT03745352 2023-06-27

Pevonedistat With Azacitidine Versus Azacitidine Alone in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid, Acute

NCT04230564 2023-06-07

Acute Myeloid Leukemia Real World Treatment Patterns

Withdrawn

Leukemia, Myeloid, Acute

NCT04264806 2022-05-20

A Study of Cusatuzumab in Combination With Azacitidine Compared With Azacitidine Alone in Patients With Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and Who Are Not Candidates for Hematopoietic Stem Cell Transplantation (HSCT)

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

NCT04296214 2021-07-09

Pharmacoeconomics in the Application of 5-azacitidine in the Treatment of Myelodysplastic Syndromes and Acute Myeloid Leukemia

Withdrawn

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT04128020 2020-10-12

Azacitidine Plus Nivolumab Following Reduced-intensity Allogeneic PBSC Transplantation for Patients With AML and High-risk Myelodysplasia

Leukemia, Myeloid, Acute

NCT03612739 2019-10-29

EPITHINK

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT03699384 2019-02-20

Safety and Clinical Activity Study of Combination Azacitidine and Avelumab in Patients With Acute Myeloid Leukemia (AML) and Minimal Residual Disease (MRD)

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT03182894 2018-08-28

Epacadostat in Combination With Pembrolizumab and Azacitidine in Subjects With Metastatic Colorectal Cancer

Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT02204020 2018-03-30

UPCI 13-165

Graft vs Host Disease, Myelodysplastic Syndromes, Recurrence, Leukemia, Myeloid, Acute

NCT02829840 2017-06-02

Dose-Escalation Study of Ponatinib, a FLT3 Inhibitor, With and Without Combination of 5-Azacytidine, in Patients With FLT3-Mutated Acute Myeloid Leukemia (AML)

Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT00842582 2016-11-02

Azacitidine With Carboplatin and Paclitaxel for Newly Diagnosed Ovarian Cancer

Gynecologic

Ovarian Neoplasms

NCT02303782 2016-09-01

A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)

Leukemia, Myeloid, Acute

NCT02701673 2016-05-04

Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed Lymphoma

Lymphoid

Lymphoma

NCT01067274 2015-12-30

ALFA-0703

Phase 3 Withdrawn